Biocon gets European Commission nod for breast cancer biosimilar
FROM THE WIRE · THEHINDUBUSINESSLINE.COM
First under new tailored clinical pathway; company’s fifth oncology biosimilar approved in Europe and the US
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRegulatory approval of an oncology drug, relevant for the stock but of ordinary scale.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The European Commission approved Biocon's breast cancer biosimilar.
- 02It is the first approved under the new tailored clinical pathway.
- 03It is the company's fifth oncology biosimilar approved in Europe and the US.